Special Issue "Patient-Derived Xenograft-Models in Cancer Research"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2020).
Interests: patient-derived models: xenografts, ex vivo tissue slices and organoid cultures; therapy resistance: castration-resistance, taxane-resistance, radioresistance; targeted imaging and radionuclide therapy: anti-PSMA and bombesin analogs; immune therapy of prostate cancer; metastasis
Conventional (2D) cell culture models are great for relatively fast and easy research, but they do not reflect the heterogeneity of clinical cancer. Realizing that models are needed that more faithfully reflect tumor complexity, a revaluation of patient-derived xenograft (PDX) models has taken place in the last two decades, instigating a revival of their use in fundamental and translational cancer research.
With the recognition that xenograft models are essential for investigating crucial aspects of tumor biology, such as tumor microenvironment, including vascularity, metastasis, and immune responses, we are, at the same time, confronted with the societal request to reduce animal research. Increasing efforts for more humanized models and with improving technology, we are now able to use optimized PDX models and highly dedicated multimodality imaging to reduce animal numbers needed for our research. Alternative PDX-based culture systems are being developed and optimized to fuel into in vitro primary (organoid) cultures and ex vivo precision-cut tissue slices.
With this Special Issue of Cancers, we wish to share cutting-edge developments and exchange expertise and know-how that are relevant across cancer types. We welcome authors to submit original research articles that will address research topics that require PDX models, highlighting their translational power:
- Tumor microenvironment
- Tumor immunology
- Alternative PDX modeling: 3D organoids and tissue slice
Dr. Wytske van Weerden
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- patient-derived xenograft models
- tumor biology
- tumor microenvironment
- tumor immunology
- thin-cut tissue slices